Filing Flows › CervoMed (CRVO) › Q1 2025
CervoMed (CRVO) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
CervoMed (CRVO) reported revenue of $1.9M for the first quarter 2025 (Q1 2025), -18% from a year earlier and -11% from the quarter before. Operating margin was -276.6%, net loss $4.9M (255.2% of revenue).
CervoMed, Q1 2025: revenue $1.9M (-18% year over year), operating margin -276.6%, net loss $4.9M, operating cash flow −$3.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.9M | -11% | -18% |
| Operating profit | −$5.3M | — | — |
| Net earnings | −$4.9M | — | — |
| Operating cash flow | −$3.9M | — | — |
What changed
Revenue was $1.9M in Q1 2025, down 18% year over year and down 11% from the previous quarter.
Operating costs exceeded revenue by $5.3M, an operating margin of -276.6%. Total costs grew 46% against a revenue fall of 18%. The fastest-growing cost line was Research & development (+72%). The quarter ended with a net loss of $4.9M, narrower than the previous quarter's $6.7M loss.
Operating cash flow was −$3.9M. Non-cash charges added back $361K of share-based compensation. Working capital and other items added $639K.
Questions
What was CervoMed's revenue in the first quarter 2025?
CervoMed (CRVO) reported revenue of $1.9M for the first quarter 2025 (Q1 2025), -18% from a year earlier and -11% from the quarter before.
Was CervoMed profitable in the first quarter 2025?
Operating loss was $5.3M (-276.6% of revenue) and net loss $4.9M.
Source: CervoMed 10-Q on SEC EDGAR.